Disease relevance of THY1

• We previously demonstrated that the breakpoint of t(11;14)(q23;q32) in the RC-K8 B cell lymphoma cell line lies between CD3 and THY1/ETS1 on chromosome 11q23, and we cloned this region and named it the rck locus [1].
• THY1 expression is associated with tumor suppression of human ovarian cancer [2].
• Based on this physical map and on our primary linkage map of the 11q23 region, we are able to confirm a preliminary localization of the gene for ataxia-telangiectasia group A (ATA) to a region centromeric to the interval defined by D11S144 (pYNB3.12) and THY1 [3].
• These findings suggest that THY1 is a good candidate tumour suppressor gene in NPC, which is significantly associated with lymph node metastases [4].
• In addition, we showed that the FLI1 region involved in the t(11;22)(q24;q12) in Ewing's sarcoma was more telomeric region that the THY1 gene by analyzing somatic cell hybrids carrying the 11q- and/or 14q+ chromosome of the t(11;14)(q23;q32) translocation, and by PFGE analysis of the YAC clone YTY17 [5].

Psychiatry related information on THY1

• Therefore, we examined this brain region from individuals with the clinical diagnosis of primary Restless Legs syndrome (RLS) and found the concentration of Thy1 was less than half that of controls [6].

High impact information on THY1

• However, Thy-1 antigen is also present on rat fibroblasts [7].
• In addition, Lesley and Lennon found that Thy-1 antigen was present on myoblasts but not myotubes of the rat L6 muscle cell line and primary cultures [7].
• K117, the putative human Thy-1 antigen, was expressed at high levels in chromosome 11-containing hybrids constructed with mouse neuroblastoma cells, but showed little or no expression in hybrids constructed with mouse L cells [8].
• Analysis of 100 X-radiation hybrid cell lines containing various fragments from the chromosomal region 11q23 showed that the ATDC gene is closely linked to THY1 [9].
• We recently mapped the gene for ataxia-telangiectasia group A (ATA) to chromosome 11q22-23 by linkage analysis, using the genetic markers THY1 and pYNB3.12 (D11S144) [10].

Chemical compound and disease context of THY1

• In our recent studies, the expression of the THY1 gene encoding a 25-28 kDa glycoprotein located at 11q23-q24, was found to be associated with complete tumor suppression of the ovarian cancer cell line SKOV-3 after the transfer of chromosome 11 [11].
• To understand the carcinogenic role of THY-1, and its downstream effects on cancer cells, a THY-1 inducible system was established in the human ovarian cancer cell line SKOV-3 based on the tetracycline (tet) regulating system [12].
• A conjugate of adriamycin and monoclonal antibodies to Thy-1 antigen inhibits human neuroblastoma cells in vitro [13].

Biological context of THY1

• After transfection of THY1 gene into HONE1 cells, a dramatic reduction of colony formation ability was observed [4].
• THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma [4].
• Clinical study showed that in 65% of NPC specimens there was either downregulation or loss of THY1 gene expression [4].
• The mechanism of THY1 gene inactivation in these cell lines was attributed to hypermethylation [4].
• These studies raised the possibility that THY1 maybe a candidate tumor suppressor gene for ovarian cancer [11].

Anatomical context of THY1

• The frequency of THY1 downregulated expression in lymph node metastatic NPC was 63%, which was significantly higher than in the primary tumour (33%) [4].
• The pMSCs isolated from bone marrow grew, attached to plastic with a fibroblast-like morphology, and expressed the mesenchymal surface marker THY1 but not the hematopoietic marker ITGAM [14].
• THY1 gene encodes a cell surface glycoprotein predominantly expressed in brain and peripheral nerves [15].
• Introduction of this gene into HeLa cells by DNA-mediated transfer results in the expression of Thy-1 antigen on the cell surface [16].
• In this study, cord blood cells with this phenotype were sorted and further separated based on their expression on the Thy-1 antigen [17].

Associations of THY1 with chemical compounds

• The gold probes, coupled to short poly-L-lysine molecules (4 kD) displayed Brownian motion, with a diffusion coefficient in the range 0.1-0.2 micron2/s. A diffusion coefficient in the 0.1 micron2/s range was also observed with 40-nm gold probes coupled to an antibody against the lipid-linked Thy-1 antigen on 3T3 fibroblasts [18].
• When grown to high density in a serum-poor medium, these cells differentiated further into typical multinucleated myotubes that expressed the M isoform of creatine kinase and increased levels of surface antigen 5.1H11, creatine kinase, and nicotinic acetylcholine receptors, but no detectable Thy 1 antigen [19].
• Immunohistochemistry was performed using anti-c-kit, OV6, Thy1, CK19, AFP, vWF and Rab3b [20].
• They were labeled in a transgenic mouse expressing Clomeleon, a chloride-sensitive fluorescent protein, under the control of the thy1 promoter [21].

Other interactions of THY1

• THY1 and CD3D genes were polymorphic after MspI digestion but no significant association was observed [22].
• A detailed restriction map of 600 kb of human chromosome band 11q23.3 has been assembled which covers the PBGD, CBL2 and THY1 genes [23].
• The differential expression levels of eight positional candidate genes, including inflammation-related THY1 and C1QTNF5, were also confirmed [24].
• Detection of MspI RFLP in human THY1 gene by the polymerase chain reaction [15].
• The human PGP9.5 gene, described here, spans 10 kb, contains nine exons and displays 5' features some common to many genes and some common with neurofilament neuron-specific enolase and Thy-1-antigen gene 5' regions [25].

Analytical, diagnostic and therapeutic context of THY1

• Using oligonucleotide microarray analysis, THY1, mapping close to a previously defined 11q22-23 nasopharyngeal carcinoma (NPC) critical region was identified as showing consistent downregulated expression in the tumour segregants, as compared to their parental tumour-suppressing microcell hybrids (MCHs) [4].
• The expression of THY1 in the transfectants was confirmed by Northern blot analysis, immunocytochemistry, and flow cytometry [11].
• A subset of mobilized CD34+ cells present in patient aphereses expresses Thy1 (CDw90) [26].
• A solid-phase radioimmunoassay, specific for the monomeric form of human Thy-1, was developed and used for quantitation of the Thy-1 antigen in human brain tissue [27].
• Co-expression in CD34+ve cells markers of differentiation (Thy1, CD133, CXCR4, c1qRp) were investigated on CD34+ve cells by double direct immunofluorescence [28].

References